BACKGROUND: We tested the hypothesis that patient-centered, streamlined human immunodeficiency virus (HIV) care would achieve lower mortality than the standard treatment model for persons with HIV and CD4 ≤ 350/uL in the setting of population-wide HIV testing. METHODS: In the SEARCH (Sustainable East Africa Research in Community Health) Study (NCT01864603), 32 communities in rural Uganda and Kenya were randomized to country-guided antiretroviral therapy (ART) versus streamlined ART care that included rapid ART start, visit spacing, flexible clinic hours, and welcoming environment. We assessed persons with HIV and CD4 ≤ 350/uL, ART eligible in both arms, and estimated the effect of streamlined care on ART initiation and mortality at 3 years. Comparisons between study arms used a cluster-level analysis with survival estimates from Kaplan-Meier; estimates of ART start among ART-naive persons treated death as a competing risk. RESULTS: Among 13 266 adults with HIV, 2973 (22.4%) had CD4 ≤ 350/uL. Of these, 33% were new diagnoses, and 10% were diagnosed but ART-naive. Men with HIV were almost twice as likely as women with HIV to have CD4 ≤ 350/uL and be untreated (15% vs 8%, respectively). Streamlined care reduced mortality by 28% versus control (risk ratio [RR] = 0.72; 95% confidence interval [CI]: .56, .93; P = .02). Despite eligibility in both arms, persons with CD4 ≤ 350/uL started ART faster under streamlined care versus control (76% vs 43% by 12 months, respectively; P < .001). Mortality was reduced substantially more among men (RR = 0.61; 95% CI: .43, .86; P = .01) than among women (RR = 0.90; 95% CI: .62, 1.32; P = .58). CONCLUSIONS: After population-based HIV testing, streamlined care reduced population-level mortality among persons with HIV and CD4 ≤ 350/uL, particularly among men. Streamlined HIV care models may play a key role in global efforts to reduce AIDS deaths.
BACKGROUND: We tested the hypothesis that patient-centered, streamlined human immunodeficiency virus (HIV) care would achieve lower mortality than the standard treatment model for persons with HIV and CD4 ≤ 350/uL in the setting of population-wide HIV testing. METHODS: In the SEARCH (Sustainable East Africa Research in Community Health) Study (NCT01864603), 32 communities in rural Uganda and Kenya were randomized to country-guided antiretroviral therapy (ART) versus streamlined ART care that included rapid ART start, visit spacing, flexible clinic hours, and welcoming environment. We assessed persons with HIV and CD4 ≤ 350/uL, ART eligible in both arms, and estimated the effect of streamlined care on ART initiation and mortality at 3 years. Comparisons between study arms used a cluster-level analysis with survival estimates from Kaplan-Meier; estimates of ART start among ART-naive persons treated death as a competing risk. RESULTS: Among 13 266 adults with HIV, 2973 (22.4%) had CD4 ≤ 350/uL. Of these, 33% were new diagnoses, and 10% were diagnosed but ART-naive. Men with HIV were almost twice as likely as women with HIV to have CD4 ≤ 350/uL and be untreated (15% vs 8%, respectively). Streamlined care reduced mortality by 28% versus control (risk ratio [RR] = 0.72; 95% confidence interval [CI]: .56, .93; P = .02). Despite eligibility in both arms, persons with CD4 ≤ 350/uL started ART faster under streamlined care versus control (76% vs 43% by 12 months, respectively; P < .001). Mortality was reduced substantially more among men (RR = 0.61; 95% CI: .43, .86; P = .01) than among women (RR = 0.90; 95% CI: .62, 1.32; P = .58). CONCLUSIONS: After population-based HIV testing, streamlined care reduced population-level mortality among persons with HIV and CD4 ≤ 350/uL, particularly among men. Streamlined HIV care models may play a key role in global efforts to reduce AIDS deaths.
Authors: Rony Zachariah; Margaret Fitzgerald; Moses Massaquoi; Olesu Pasulani; Line Arnould; Simon Makombe; Anthony D Harries Journal: AIDS Date: 2006-11-28 Impact factor: 4.177
Authors: Andrew Boulle; Peter Bock; Meg Osler; Karen Cohen; Liezl Channing; Katherine Hilderbrand; Eula Mothibi; Virginia Zweigenthal; Neviline Slingers; Keith Cloete; Fareed Abdullah Journal: Bull World Health Organ Date: 2008-09 Impact factor: 9.408
Authors: Elvin H Geng; David R Bangsberg; Nicolas Musinguzi; Nneka Emenyonu; Mwebesa Bosco Bwana; Constantin T Yiannoutsos; David V Glidden; Steven G Deeks; Jeffrey N Martin Journal: J Acquir Immune Defic Syndr Date: 2010-03 Impact factor: 3.731
Authors: Maya Petersen; Laura Balzer; Dalsone Kwarsiima; Norton Sang; Gabriel Chamie; James Ayieko; Jane Kabami; Asiphas Owaraganise; Teri Liegler; Florence Mwangwa; Kevin Kadede; Vivek Jain; Albert Plenty; Lillian Brown; Geoff Lavoy; Joshua Schwab; Douglas Black; Mark van der Laan; Elizabeth A Bukusi; Craig R Cohen; Tamara D Clark; Edwin Charlebois; Moses Kamya; Diane Havlir Journal: JAMA Date: 2017-06-06 Impact factor: 56.272
Authors: Dalsone Kwarisiima; Moses R Kamya; Asiphas Owaraganise; Florence Mwangwa; Dathan M Byonanebye; James Ayieko; Albert Plenty; Doug Black; Tamara D Clark; Bridget Nzarubara; Katherine Snyman; Lillian Brown; Elizabeth Bukusi; Craig R Cohen; Elvin H Geng; Edwin D Charlebois; Theodore D Ruel; Maya L Petersen; Diane Havlir; Vivek Jain Journal: J Int AIDS Soc Date: 2017-07-21 Impact factor: 5.396
Authors: Frédérique Chammartin; Kathrin Zürcher; Olivia Keiser; Ralf Weigel; Kathryn Chu; Agnes N Kiragga; Cristina Ardura-Garcia; Nanina Anderegg; Christian Laurent; Morna Cornell; Hannock Tweya; Andreas D Haas; Brian D Rice; Elvin H Geng; Matthew P Fox; James R Hargreaves; Matthias Egger Journal: Clin Infect Dis Date: 2018-11-13 Impact factor: 9.079